Michael Lochhead is Executive Vice President and Chief Technology Officer at MBio Diagnostics, Inc., a life sciences technology development company. Mike is a company co-founder and he has led the growth of the company’s technical program from lab concept to research programs on five continents. He has overall responsibility for a multidisciplinary, integrated team of bioscience, engineering, and business professionals. Mike is also responsible for product and intellectual property strategy as well as directly supporting the CEO and Board of Directors in corporate strategy and fundraising.
His major development programs at MBio focus on human clinical diagnostics and veterinary testing, as his group also has product development activities in food and environmental testing. He has responsibility for the company’s commercial partnerships, and he is Principal Investigator on programs with the National Institutes of Health and DARPA. Prior to joining MBio, Mike successfully developed and commercialized microarray surface chemistry products while at Accelr8 Technology Corporation (now Accelerate Diagnostics). Mike’s professional career began in academia at the University of New Hampshire, where he was an assistant professor in the Department of Chemical Engineering. He is co-inventor on multiple issued and pending U.S. and international patents.
Mike earned his PhD in Chemical Engineering from the University of Wisconsin, Madison and completed his post-doctoral training in Bioengineering at the University of Washington, Seattle. He holds bachelor’s degrees in both Chemical Engineering and Government from the University of Notre Dame.